Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Hospitalizations because of adverse drug reactions in elderly patients admitted through the emergency department: a prospective survey.

• Pascale Olivier, Lionel Bertrand, Marie Tubery, Dominique Lauque, J. -L. Montastruc, Maryse Lapeyre-Mestre
• Drugs & aging
• 2009

BACKGROUND AND OBJECTIVES Several studies have been conducted to determine the frequency and characteristics of adverse drug reactions (ADRs) in elderly populations, focusing on those leading to… (More)

The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.

• Pascale Olivier, J. -L. Montastruc
• Pharmacoepidemiology and drug safety
• 2006

INTRODUCTION Because of design, objectives and number of included subjects, clinical studies are insufficient to assess the safety of new drugs. Sometimes, serious adverse drug reactions (ADRs) led… (More)

Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice: a study in a French emergency department.

• Pascale Olivier, Olivier Boulbés, Marie Tubery, Dominique Lauque, J. -L. Montastruc, Maryse Lapeyre-Mestre
• Drug safety
• 2002

OBJECTIVE To assess the preventability of adverse drug reactions (ADRs) leading to hospital admissions and to investigate the feasibility of the use of a standardised preventability scale in clinical… (More)

[Validation of a measurement scale: example of a French Adverse Drug Reactions Preventability Scale].

• Pascale Olivier, J. Raymond Caron, +7 authors Maryse Lapeyr-Mestre
• Therapie
• 2005

Adverse drug reactions (ADRs) have been recognised as an important cause of hospital admission. Most of these drug-related admissions were expected ADRs and, thus, partly preventable. However, as far… (More)

Overview of adverse reactions to nefopam: an analysis of the French Pharmacovigilance database

• Geneviève Durrieu, Pascale Olivier, Haleh Bagheri, Jean Louis Montastruc
• Fundamental & clinical pharmacology
• 2007

Nefopam is widely used for the relief of moderate acute pain. Its safety profile remains to be specified. The objective of the study was to review adverse reactions to nefopam spontaneously reported… (More)

Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.

• Jean-Louis Montastruc, Agnés Sommet, +5 authors Haleh Bagheri
• Joint, bone, spine : revue du rhumatisme
• 2006

Adverse Drug Reactions Involving Protein Kinase Inhibitors: A French Pharmacovigilance Database Study Comparing Safety in Younger and Older Patients (≥ 75 years) with Cancer

• Vincent Clapes, Vanessa Rousseau, Fabien Despas, Jean-Louis Montastruc, Pascale Olivier
• Pharmaceutical Medicine
• 2018

Despite the increasing incidence of cancers in elderly people, this population remains under-represented in clinical trials. As a result, data describing the safety and efficacy of protein kinase… (More)

Serious adverse drug events related to non-investigational drugs in academic clinical trials: another source of safety data for risk assessment?

• Pascale Olivier, Anne Gimbert, +5 authors N Petitpain
• British journal of clinical pharmacology
• 2016

AIMS Sponsors of clinical trials have to analyze serious adverse events (SAEs). Both sponsors and investigators determine the relationship between the investigational medicinal product, the… (More)

COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database

• Geneviève Durrieu, Pascale Olivier, Jean Louis Montastruc
• European Journal of Clinical Pharmacology
• 2005

To evaluate the main characteristics of case reports of arterial hypertension (AH) related to COX-2 inhibitor (coxib) use in real-life practice. This study was based on spontaneous reports of adverse… (More)

[Post-marketing safety profile of avocado-soybean unsaponifiables].

• Pascale Olivier, J. -L. Montastruc
• Presse medicale
• 2010

AIM To determine the post-marketing safety profile of avocado-soybean unsaponifiables since their commercialization in France until 2008. METHODS We used data provided by French spontaneous… (More)

• ‹
• 1
• 2
• 3
• ›